News

ZyVersa Therapeutics Kicks Off Patient Recruitment for VAR 200

ZyVersa Therapeutics Kicks Off Patient Recruitment for VAR 200

ZyVersa Therapeutics Begins Patient Recruitment for VAR 200

In a significant advancement, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has announced the activation of its first clinical site for the VAR 200 Phase 2a clinical trial. This trial aims to recruit patients suffering from diabetic kidney disease (DKD), marking a pivotal step in the journey towards developing innovative therapies for kidney-related complications.

Importance of VAR 200 in Treating Kidney Disease

VAR 200 represents a potential first-in-class drug specifically addressing renal lipotoxicity, a condition that adversely affects the kidneys' filtration system. Current treatments fail to target this critical pathway, leading to issues such as proteinuria and progressive kidney damage. The Phase 2a clinical trial will evaluate the drug's effectiveness in providing relief from these complications.

Preclinical Data and Future Expectations

Preclinical studies have highlighted VAR 200’s ability to decrease cholesterol and lipid buildup, offering protection against renal injury and fibrosis. The drug has shown promise across various types of kidney disease, including DKD, Focal Segmental Glomerulosclerosis, and Alport Syndrome. In particular, the upcoming Phase 2a study will offer the first proof-of-concept data in humans, which is eagerly anticipated in the coming years.

Collaboration with Experts

Further driving the trial is the involvement of the Clinical Advancement Center, PLLC, located in San Antonio, Texas, and led by Dr. Pablo Pergola. The collaboration aims to develop cutting-edge treatments that can reshape the treatment landscape for patients with kidney diseases. ZyVersa’s Co-founder and CEO, Stephen C. Glover, emphasizes the urgency of addressing kidney lipotoxicity and its role in DKD progression.

Clinical Study Details

The Phase 2a trial is designed as an open-label study spanning 16 weeks, which includes 12 weeks of treatment followed by a four-week follow-up. Patients will receive intravenous administration of VAR 200 twice a week, supplemented alongside their existing medication regimen. The primary efficacy endpoint will focus on the change in urinary albumin to creatinine ratio, a key marker of kidney function.

Understanding Cholesterol Efflux Mediator™ VAR 200

Cholesterol Efflux Mediator™ VAR 200, which is also referred to as 2-hydroxypropyl-beta-cyclodextrin (2HP?CD), is an injectable drug aimed at alleviating the detrimental accumulation of lipids in the kidneys. This unique formulation works both passively and actively to remove excess lipids, showing significant preclinical promise in animal studies.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is dedicated to delivering first-in-class therapeutics to patients with renal and inflammatory diseases. With a robust pipeline of innovative drug candidates, including VAR 200 and an Inflammasome ASC Inhibitor, ZyVersa is committed to meeting the urgent medical needs of patients suffering from conditions that currently have inadequate treatment options. To learn more about their work and developments, individuals are encouraged to visit the company’s website.

Frequently Asked Questions

What is the purpose of the VAR 200 clinical trial?

The VAR 200 clinical trial aims to evaluate the efficacy and safety of the drug in patients with diabetic kidney disease, focusing on its impact on kidney function.

How does VAR 200 work?

VAR 200 potentially works by alleviating renal lipid accumulation and enhancing cholesterol efflux, which are vital in managing kidney health.

Where is the first clinical site located?

The first clinical site is the Clinical Advancement Center, PLLC in San Antonio, Texas.

What are the expected outcomes of this trial?

The trial aims to provide proof-of-concept data demonstrating the effectiveness of VAR 200 in improving kidney-related parameters in patients.

How can patients participate in the trial?

Patients interested in participating should contact the clinical trial site directly for information regarding eligibility and enrollment procedures.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 34

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 55

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 183

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 67

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 147

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 0

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 65

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading

Top 5 Most Recently Viewed Articles

First Advantage to Engage Investors at Wolfe FinTech Forum

Updated Category News Views 219

First Advantage to Engage Investors at Wolfe FinTech Forum ATLANTA, March 04, 2025 — First Advantage Corporation (NASDAQ: FA), renowned as a premier provider in employment background screening, identity verification, and other related solutions, is set to showcase its offerings at an upcoming pivotal event. Management of First Advantage will participate in a fireside...

Continue Reading
European Markets Open Strong: EV Collaborations Boost Sentiment

Updated Category News Views 140

European Markets Show Positive Trends European stock markets are beginning the week on a high note, reflecting a cautiously optimistic mood among investors. The overall sentiment is driven by various factors that are currently in play within the financial landscape. The DAX in Germany has risen by 0.4%, while France's CAC 40 has increased by 0.7%. In contrast, the FTSE...

Continue Reading
Southern Company Stock Reaches New Heights, Driven by Growth

Updated Category News Views 81

Southern Company Achieves Record Stock Price Southern Company (NYSE: SO) has recently celebrated a remarkable achievement with its stock price hitting a record high of $91.87. This surge marks an impressive 36.84% increase over the past year, showcasing a growing optimism among investors in the energy sector. The company has been proactive in expanding its operations...

Continue Reading
Exploring GDP Trends: Navigating Economic Uncertainties

Updated Category News Views 337

Understanding Recent GDP Trends The latest economic indicators reveal complexities that question the idea of a resilient economy. Despite these challenges, we remain optimistic for the time being. Let's take a closer look at the current situation: GDP Growth Rate Adjustments The Atlanta Fed’s GDPNow tracking model recently revised its estimated growth rate for the first...

Continue Reading
Live Nation's Ticket Sales Surge Amid Mixed Earnings Report

Updated Category News Views 347

Overview of Live Nation's Recent Performance Live Nation Entertainment, Inc. (NYSE: LYV) witnessed a notable decline in its stock price after the announcement of third-quarter earnings that did not meet market expectations. Despite the drop, the company reported impressive ticket sales and revenue growth. Financial Highlights The entertainment giant reported a substantial...

Continue Reading